Introduction
Artificial Intelligence and Machine Learning are no longer distant promises in clinical research. For several years, AI has been discussed as a potential accelerator for clinical trials, often through innovation pilots, proof-of-concepts, and isolated experiments. Today, the conversation is changing.
AI is gradually moving from experimentation to embedded operational practice.
In Clinical Operations, this shift is particularly visible in areas where teams manage high volumes of structured and unstructured information: protocol interpretation, study start-up, database configuration, feasibility assessment, risk monitoring, documentation, and oversight. These are not abstract use cases. They are operational pressure points that directly influence timelines, quality, cost, and decision-making.
The question is no longer simply: “Can AI support clinical trials?”
The more relevant question is now: “How can AI deliver measurable operational value while remaining trustworthy, traceable, and compliant when it touches GxP-relevant processes?”
This is where the next challenge begins.
From AI Pilots to Embedded Operational Practice
For many organizations, AI adoption in clinical research started with isolated pilots. These initiatives were often designed to test technical feasibility, explore automation potential, or demonstrate innovation. While useful, pilots rarely transform operations on their own.
The industry is now entering a more mature phase. AI is increasingly being positioned as part of the clinical trial infrastructure itself.
Recent developments show this direction clearly. ICON, for example, has announced a strategic partnership with Microsoft to scale Orbis, its secure and governed agentic AI platform, across the clinical trial lifecycle. The stated ambition includes AI-enabled protocol digitization, study design, feasibility, site identification, start-up, monitoring, data review, regulatory documentation, and real-time detection of operational signals. Such vendor moves are cited here as market signals of this shift, not as endorsements of specific platforms. (1)
This matters because it reflects a broader transition: AI is no longer sitting outside the clinical operations model. It is entering the workflows where decisions are made, risks are detected, and execution is coordinated.
At the same time, European regulators are preparing the clinical trial environment for smarter, faster and more data-driven approaches. The ACT EU 2026–2027 workplan, led by the European Commission, HMA and EMA, highlights regulatory, technological and process innovation, with priorities including clinical trial data analytics, risk-based approaches, AI use in clinical trials, paediatric clinical trials and platform trials. (2)
For Clinical Operations teams, this shift creates an important responsibility. Embedding AI is not just a technology project. It requires operational readiness, cross-functional alignment and a clear understanding of where AI outputs influence trial execution.
Use-Case-Led ROI in Clinical Operations
The strongest AI opportunities are not necessarily the most impressive from a technological perspective. They are the ones that solve concrete operational problems.
One of the clearest examples is protocol interpretation and study database configuration.
In many trials, the transition from final protocol to Electronic Data Capture design remains time-consuming and variable. Teams must interpret protocol requirements, define visits and forms, apply standards, configure fields, create code lists, prepare edit checks and ensure consistency across downstream processes. Manual interpretation can introduce variability, rework and delays.
IQVIA’s EDC Recommender illustrates how AI can support this process. The solution reads a digital protocol, applies defined business rules and reuses components from a centralized EDC design library to generate a protocol-specific EDC design. According to IQVIA, this can help automate repetitive design activities such as visits, forms, fields, code lists and edit checks, with reported time savings of up to 62% in initial EDC design. Importantly, IQVIA also states that the tool does not remove expert review or governance. (3)
This is a strong example of use-case-led ROI.
The value is not simply that AI exists. The value is that it targets a specific bottleneck, reduces manual effort, improves standardization and allows expert teams to focus on study-specific decisions.
For sponsors and CROs, this type of use case can support faster study start-up, more predictable database build timelines and better consistency across studies. For Clinical Project Managers, it also changes the nature of oversight. The task is no longer only to track whether an activity has been completed. It is to understand whether the AI-supported process has been correctly governed, reviewed, documented and aligned with the protocol and study objectives.
This is particularly important in complex trials, where early operational decisions can affect downstream data cleaning, SDTM mapping, analysis readiness and inspection preparedness.
The Governance Gap
As AI becomes embedded in clinical operations, governance becomes the critical issue.
In January 2026, FDA and EMA published ten Good AI Practice principles for AI use in drug development. These principles emphasize a human-centric design, a risk-based approach, clear context of use, multidisciplinary expertise, data governance and documentation, risk-based performance assessment and lifecycle management. The publication also stresses the importance of reliability, patient safety and regulatory excellence. (4)
In Europe, this is reinforced by the EU AI Act (Regulation (EU) 2024/1689), which classifies certain AI systems used in health-related or clinical decision-making contexts as “high-risk” and adds transparency, human-oversight and documentation obligations that overlap with existing GxP expectations. (5)
These expectations are highly relevant for Clinical Operations.
When AI supports a low-risk administrative task, governance requirements may be relatively simple. But when AI influences protocol interpretation, database configuration, risk signals, data review or GxP-relevant decisions, the level of oversight must increase.
Organizations need to define:
Who owns the AI-enabled process?
Who validates the output?
Who approves exceptions or overrides?
How are decisions documented?
How are changes to the protocol, model, data or business rules managed?
What evidence would be available during an audit or inspection?
This is the governance gap. The frameworks now exist — the gap is not a missing standard but the translation of these principles into day-to-day ownership: named roles, SOPs and responsibilities inside Clinical Operations.
AI may accelerate workflows, but acceleration without traceability creates risk. A recommendation that cannot be explained, challenged or reconstructed may be difficult to trust in a regulated environment.
This is why the idea of “glass-box” AI is becoming increasingly important. Applied Clinical Trials recently highlighted the need to move away from black-box approaches and toward AI systems where sponsors can embed SOPs, protocol context and governance frameworks, with traceability of outputs so teams can validate and trust what the system produces. (6)
In other words, trust cannot be added at the end. It must be designed into the operating model.
Accountability, in particular, does not transfer with the task. Under ICH GCP, the sponsor retains ultimate responsibility for trial conduct and data integrity even when a CRO or technology vendor operates the AI — so “who owns oversight?” is a question sponsors must answer explicitly, not delegate by default. (7)
What This Means for Clinical Project Management
The rise of AI does not reduce the importance of Clinical Project Management. It increases it.
As AI becomes embedded in clinical trial workflows, Clinical Project Managers will play a key role in connecting technology, process, quality and people. Their value will not be limited to timeline tracking or meeting coordination. It will sit at the intersection of operational execution, risk management, vendor oversight, documentation, escalation and cross-functional decision-making.
A Clinical Project Manager will need to understand where AI is used, what it is used for, what risks are associated with the use case and which decisions remain under human responsibility. A growing part of this is vendor oversight: when the AI capability is delivered by a CRO or technology provider, project leads must be able to see how the tool was validated, how its outputs are controlled, and where the human decision points sit.
This requires collaboration between Clinical Operations, Data Management, Biostatistics, Quality Assurance, Regulatory Affairs, Safety, vendors and technology providers. It also requires a practical mindset. AI governance should not become a theoretical framework disconnected from daily trial execution. It must be translated into workflows, roles, responsibilities, documentation and review practices.
For small and mid-sized biotech, medtech and pharmaceutical companies, this point is especially important. These organizations may not always have large internal infrastructure to manage AI-enabled operating models. They will need partners who can help them ask the right questions, structure oversight and keep execution both efficient and inspection-ready.
Conclusion
AI and Machine Learning are becoming part of the clinical operations landscape. The opportunity is real: faster study start-up, more consistent database design, better risk detection, improved data review and more efficient decision-making.
But the future of AI in clinical trials will not be determined by automation alone.
It will depend on governance.
The organizations that succeed will be those that move beyond experimentation and embed AI into clinical operations with clear context of use, human oversight, traceability, accountability and patient safety at the center.
For Clinical Operations leaders, the priority is not to adopt AI for the sake of innovation. It is to identify the right use cases, measure the operational value, define ownership and ensure that every AI-supported process remains aligned with quality, compliance and trust.
Because in clinical research, speed matters.
But only when it helps deliver reliable evidence, protect patients and bring meaningful innovation closer to those who need it.
References
(1) ICON — ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development, June 22, 2026. https://www.iconplc.com/news-events/press-releases/icon-selects-microsoft-preferred-technology-partner-power-ai-enabled
(2) ACT EU / European Commission / HMA / EMA — ACT EU Workplan 2026–2027, May 2026. https://accelerating-clinical-trials.europa.eu/document/download/efcee52a-5c93-43c2-b5f2-d1479335fdc4_en?filename=ACT+EU+workplan+2026-2027.pdf
(3) IQVIA — Electronic Data Capture Recommender, Fact Sheet, July 1, 2026. https://www.iqvia.com/library/fact-sheets/electronic-data-capture-recommender
(4) FDA / EMA — Guiding Principles of Good AI Practice in Drug Development, January 2026. https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development
(5) European Union / ICH — Regulation (EU) 2024/1689 (Artificial Intelligence Act), 2024; https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32024R1689
(6) Applied Clinical Trials — Making AI a Glass Box, Not a Black Box, in Clinical Trials, June 2026. https://www.appliedclinicaltrialsonline.com/view/ai-glass-box-black-box-clinical-trials
(7)ICH E6(R3) Good Clinical Practice, 2025. EU AI Act: https://www.fda.gov/media/169090/download?attachment=
